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Detection of opsonizing antibodies 
directed against a recently 
circulating Bordetella pertussis 
strain in paired plasma samples 
from symptomatic and recovered 
pertussis patients
Elise S. Hovingh1,2, Betsy Kuipers1, Axel A Bonačić Marinović1, Hendrik Jan Hamstra1, 
Danielle Hijdra1, Lapo Mughini Gras1,3, Inonge van Twillert1, Ilse Jongerius1,2,4, 
Cecile A. C. M. van Els1 & Elena Pinelli1
Correlates of protection (CoPs) against the highly contagious respiratory disease whooping cough, 
caused by Bordetella pertussis, remain elusive. Characterizing the antibody response to this pathogen 
is essential towards identifying potential CoPs. Here, we evaluate levels, avidity and functionality of 
B. pertussis-specific-antibodies from paired plasma samples derived from symptomatic and recovered 
pertussis patients, as well as controls. Natural infection is expected to induce protective immunity. 
IgG levels and avidity to nine B. pertussis antigens were determined using a novel multiplex panel. 
Furthermore, opsonophagocytosis of a B. pertussis clinical isolate by neutrophils was measured. 
Findings indicate that following infection, B. pertussis-specific antibody levels of (ex-) pertussis patients 
waned, while the avidity of antibodies directed against the majority of studied antigens increased. 
Opsonophagocytosis indices decreased upon recovery, but remained higher than controls. Random 
forest analysis of all the data revealed that 28% of the opsonophagocytosis index variances could be 
explained by filamentous hemagglutinin- followed by pertussis toxin-specific antibodies. We propose 
to further explore which other B. pertussis-specific antibodies can better predict opsonophagocytosis. 
Moreover, other B. pertussis-specific antibody functions as well as the possible integration of these 
functions in combination with other immune cell properties should be evaluated towards the 
identification of CoPs against pertussis.
Whooping cough, a highly contagious respiratory disease caused by the Gram-negative bacterium Bordetella 
pertussis, has resurged despite high vaccine coverage1,2. In the 1990s, the whole cell pertussis vaccine was replaced 
by the current acellular pertussis vaccine (ACV) in many industrialized countries. The ACV effectively prevents 
disease. However, protective immunity is lost 4–7 years post-vaccination and this vaccine does not protect against 
transmission3–5 urging the development of an improved vaccine. Evaluating pertussis vaccine-induced protection 
poses a problem as correlates of protection (CoPs)6 against pertussis have not been defined. A CoP can be defined 
as an (immune) marker that statistically correlates with vaccine efficacy but is not necessarily mechanistically 
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responsible for protection6. While high levels of anti-pertussis toxin (Ptx) have been shown to be indicative for 
protection against disease, no reliable threshold has been established7–9. It is widely accepted that a well-defined 
CoP will not be unveiled merely by monitoring the antibody levels induced by the ACV10,11. In addition to the 
quantity, the quality and functionality of antibodies should also be evaluated12. This has not been extensively 
studied in pertussis, as typically IgG levels and isotypes are measured13.
For pertussis, a CoP would ideally correlate with the inability of the bacterium to colonise the airways and 
would hence correlate with protection from transmission of this pathogen. One of the functions of antibodies is 
to facilitate the uptake of bacteria via Fc-γ-receptor-mediated opsonophagocytosis by, for example, neutrophils 
which play an important role in clearing B. pertussis during infection and thus in preventing colonisation14. The 
relevance of avidity, indicating the strength by which the antibody binds the antigen, in relation to opsonophago-
cytosis has not been documented for B. pertussis. However, antibody avidity has been shown to be important for 
opsonophagocytosis of other bacteria including Streptococcus pneumoniae15.
Natural infection with B. pertussis induces a strong immune response across all age groups13. Compared to 
vaccine-induced protection, it provides the longest protection from disease with estimates of up to 20 years3. In an 
attempt to identify CoPs, we evaluated the levels and quality of antibodies directed against nine different virulence 
factors as well as the functionality of B. pertussis-specific antibodies in paired plasma samples of symptomatic as 
well as recovered pertussis patients, who are expected to have protective immunity conferred by natural infection. 
These antigens included the well-studied ACV components, Ptx, pertactin (Prn), filamentous hemagglutinin 
(FHA) and fimbriae (Fim) 2 and 3 and the virulence factors lipooligosaccharide (LOS), Bordetella resistance 
to killing A (BrkA), virulence associated gene 8 (Vag8) as well as whole outer membrane vesicles (OMVs). The 
antibody functionality was assessed by means of an antibody-mediated opsonophagocytosis assay (OPA) using 
a recently circulating B. pertussis strain. Moreover, integrated analysis of the generated data on levels and avidity 
was performed in an attempt to identify B. pertussis-specific antibodies predictive for opsonophagocytosis of this 
pathogen as potential CoPs against pertussis.
Results
Waning of antigen-specific antibodies years after B. pertussis infection. To characterize the nat-
ural antibody response to B. pertussis we determined levels of IgG, not only against the well-studied vaccine 
antigens Ptx, FHA, Prn, Fim2 and Fim313,16, but also against Vag8, BrkA, LOS and OMVs using paired plasma 
samples of symptomatic and recovered pertussis patients and controls (Fig. 1).
The levels of antibodies against Ptx, FHA, Prn, OMVs, LOS, BrkA and Vag8 were significantly higher in plasma 
of symptomatic patients compared to the controls (Fig. 2A–G). The levels of antibodies against Fim2 and Fim3 did 
not significantly differ from controls (Fig. 2H and I). For the recovered patients, the levels of the specific antibodies 
for all tested antigens were significantly lower compared to that of the symptomatic patients. The Ptx-, FHA- and 
Prn-specific antibody levels for the recovered patients remained significantly higher than the controls (Fig. 2A–C) 
whereas those of OMV-, LOS-, BrkA-, Vag8-, Fim2- and Fim3-specific antibodies did not (Fig. 2D–I).
Avidity maturation of B. pertussis-specific antibodies depends on antigen specificity. In addi-
tion to IgG levels in plasma, we determined the avidity of antigen-specific IgG antibodies in plasma of symp-
tomatic and recovered pertussis patients. The avidity index (AI) of the OMV-, LOS-, BrkA-, Vag8-, Fim2- and 
Fim3-specific antibodies were significantly higher for the recovered compared to the symptomatic patients 
(Fig. 3A–F). The significant difference for BrkA-IgG should be interpreted with caution as the AI is low. The AI of 
FHA-specific antibodies was significantly but modestly decreased for the recovered compared to the symptomatic 
patients (Fig. 3G). No significant difference in AI of Ptx- and Prn-specific antibodies was observed (Fig. 3H and I).
Opsonophagocytosis wanes within years after infection but remains higher compared to controls. 
Since antibody-mediated opsonophagocytosis is important for the clearance of B. pertussis during infection14, 
we analysed the functionality of the B. pertussis- specific antibodies using the OPA. Opsonophagocytosis by 
primary neutrophils was assessed using the clinical B. pertussis isolate B191717, which was modified to express 
Figure 1. Schematic representation of SKI plasma samples used in this study. 100 plasma samples were selected 
from the SKI study which included 40 paired samples from symptomatic or recovered (ex) pertussis patients 
and 20 samples from controls.
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green fluorescent protein (GFP). We observed significantly lower opsonophagocytosis indices in plasma samples 
from recovered compared to symptomatic patients. Notably, the opsonophagocytosis indices from the recovered 
patients remained significantly higher than those of the controls (Fig. 4).
Lower IgG levels, opsonophagocytosis indices and higher avidities of B. pertussis-antibodies 
are generally observed for recovered compared to symptomatic patients. In order to analyse all 
the obtained data, a PCA was performed based on the IgG levels and avidity as well as the opsonophagocytosis 
indices. As shown in Fig. 5, the three groups of the cohort form clusters, with the symptomatic patients positioned 
furthest away from the controls and the recovered patients being positioned in between. The lines depict the 
inter-correlations of the various parameters measured in all samples. Firstly, the lines indicate that the axes of 
differentiation of the majority of the antibody levels had similar alignments and were mainly directed towards the 
Figure 2. Levels of IgG antibodies directed against nine different pertussis antigens. Antibodies directed against 
(A) Ptx, (B) FHA, (C) Prn, (D) OMV, (E) LOS, (F) BrkA, (G) Vag8, (H) Fim3 and (I) Fim2 were determined 
using a 9-valent multiplex immunoassay platform using plasma samples collected from symptomatic (circles) 
and recovered (squares) pertussis patients as well as from controls (triangles). Statistical testing: one-way 
analysis of variance (ANOVA) followed by post-hoc tests (Welch Two Sample t-test or paired t-test). The false 
discovery rate was controlled at the level of 10% by applying the Benjamini-Hochberg method. *p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001 ****p ≤ 0.0001 ns = non-significant. Data shown in A–I represent the geometric 
mean ± geometric SD.
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higher scores of the two principal components, mostly populated by the symptomatic group. Secondly, the axes 
of differentiation of the avidities pointed mainly in the direction of the recovered group. This analysis reflects the 
findings represented in Figs 2 and 3 which show lower antibody levels and higher AI in the recovered versus symp-
tomatic patients for most of the studied antigens. Likewise, the PCA reflects the findings presented in Fig. 4 where 
the axes of differentiation of the opsonophagocytosis indices pointed in the direction of the symptomatic group.
Random forest analysis reveals predictive value of FHA and Ptx antibodies for opsonophagocytosis 
indices. A random forest (RF) analysis was performed to determine which of our measured variables, namely 
effective-IgG levels as well as age and sex, was most predictive for the observed opsonophagocytosis and may 
serve as potential CoPs. The analysis showed that 28% of the variance of the opsonophagocytosis indices is 
explained by our model. Results indicate that FHA- followed by Ptx-specific antibodies are most predictive for the 
accounted variances in the opsonophagocytosis indices (Fig. 6). Multiple linear regression analysis with the same 
variables considered in the RF analysis revealed significant p-values for FHA and Ptx effective-IgGs supporting 
their potential predictive role (Table 1).
Figure 3. Avidity of IgG antibodies directed against nine different pertussis antigens. Avidity Index (AI) of 
antibodies directed against (A) OMVs, (B) LOS, (C) BrkA, (D) Vag8, (E) Fim2, (F) Fim3, (G) FHA, (H) Ptx 
and (I) Prn were determined in collected from symptomatic (circles) and recovered (squares) pertussis patients. 
Statistical testing: paired t-test. The false discovery rate was controlled at the level of 10% by applying the 
Benjamini-Hochberg method. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001 ****p ≤ 0.0001 ns = non-significant. Data 
shown in A–I represent the mean ± SD.
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Discussion
In the attempt to identify serological CoPs against pertussis, our study pioneers by integrating the dynamics of 
different antibody properties. These include their specificity to nine different B. pertussis antigens, their avidity 
and functional capacity to opsonise live B. pertussis. These assays were performed using paired plasma samples 
from symptomatic and recovered pertussis patients, who are expected to have protective immunity conferred by 
natural infection. As previously shown, the levels of antibodies to Ptx, FHA, Prn, Fim2, Fim3 and OMVs waned 
years after infection13. Antibodies against the other studied antigens, BrkA, Vag8 and LOS, also decreased when 
patients had recovered from clinical disease. BrkA, Vag8 and LOS were included in this study because they are 
outer membrane antigens and could be anchors for antibody-mediated phagocytosis.
Besides the waning of B. pertussis-specific antibody levels, we also show avidity maturation for the majority 
of specific antibodies years after B. pertussis infection with the exception of Prn, FHA and Ptx. High avidity 
Figure 4. Opsonophagocytosis indices wane years after pertussis infection. Antibody-mediated 
opsonophagocytosis indices were determined using paired plasma samples collected from symptomatic (circles) 
and recovered (squares) pertussis patients. Plasma samples from controls (triangles) were also included. 
Statistical testing: one-way analysis of variance (ANOVA) followed by post-hoc tests (Welch Two Sample t-test 
or paired t-test). The false discovery rate was controlled at the level of 10% by applying the Benjamini-Hochberg 
method. ****p ≤ 0.0001. Data shown represent the mean ± SD.
Figure 5. PCA of all obtained data. PCA was performed based on the antibody levels, AI and 
opsonophagocytosis indices for all plasma samples used in this study. The axes of differentiation of the antibody 
levels and AI are shown by the lines. Plasma samples collected from symptomatic patients are depicted as red 
dots, from recovered patients as blue squares and from controls as green triangles. The red, blue and green 
ellipses indicate clustering of the symptomatic, recovered and control samples, respectively. Lines indicate the 
axes of differentiation of the different parameters measured in this study.
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antibodies are classically secreted by specific B cells that are positively selected during repeated exposures in ger-
minal centre reactions18. In contrast to our findings, avidity maturation of Ptx antibodies was previously shown 
in paired samples of pertussis patients19. This difference may be due to the time between collections of the paired 
samples, which in our case was on average three years instead of four weeks after diagnosis as performed in the 
before mentioned study. Avidity of antibodies has also been measured following ACV booster vaccination. The 
authors showed that Ptx and Prn antibody avidity increased one year post-vaccination20. This emphasizes that in 
the search for CoPs against pertussis it is important to consider the antibody kinetics, not only of the levels but 
also of the avidity, which may differ following infection or vaccination21.
During an infection with B. pertussis, neutrophils infiltrate the lung where they are important for the clearance 
of this respiratory pathogen14. Here, we show that three years after infection opsonophagocytosis indices decrease 
but remain significantly higher compared to the controls. This is the first reported B. pertussis-specific opsono-
phagocytosis assay using the recently isolated B. pertussis clinical strain B1917 instead of the laboratory strain 
Tohama I, which has been used in the past. B1917 has the advantage of being a representative strain for the strains 
Figure 6. Random Forest analysis integrating all available data. Random Forest analysis was performed using 
a model that includes the log transformed values of the effective-IgG levels directed against the nine different 
antigens, as well as the age and sex of the participants. R2 represents the fraction of the total opsonophagocytosis 
indices variance which can be explained by variations in the effective-IgG levels, where a value of 1 would mean 
that the variance in the measured opsonophagocytosis indices is solely explained by the considered predictive 
variables. The percentage of increase in the mean square error (%IncMSE) after randomly permuting the values 
of the considered predictive variables gives an indication of how influential each considered variable is on 
predicting OPA values to the extent of the OPA variance which can be explained by the model (R2).
(log10 (IgG x Avidity) Estimate Std. Error p-value
Prn 0.002 0.064 0.977
FHA 0.350 0.110 0.002
Fim2 −0.183 0.079 0.023
Fim3 0.172 0.085 0.045
Ptx 0.225 0.092 0.017
LOS −0.055 0.168 0.743
Vag8 0.073 0.125 0.562
OMV 0.062 0.196 0.753
BrkA 0.117 0.088 0.187
Age 0.003 0.002 0.247
Sex 0.009 0.011 0.433
Table 1. Multi-linear regression analysis with the same parameters considered in the random forest analysis 
using the effective-IgG levels (IgG levels and avidity).
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that were circulating at the time of our clinical study17. The OPA here described can discriminate between con-
trols, symptomatic and recovered (ex) pertussis patients. Based on these findings, we propose antibody-mediated 
opsonophagocytosis of B. pertussis as a possible CoP against pertussis. Assays which measure the capacity of 
antibodies to opsonize pathogens for phagocytosis are currently used in the field of pneumococcal vaccination11. 
Opsonophagocytosis has also been shown to correlate with protection against malaria22.
Analysis of our data with the RF model using effective-IgGs levels of B. pertussis-specific antibodies uncovered 
FHA- followed by Ptx-antibodies as being the two variables that best predict the opsonophagocytosis indices. These 
findings corroborate earlier studies in which the authors also found a correlation between FHA- and to a lesser 
extend Ptx-specific antibodies and opsonophagocytosis23. In contrast to our findings, others have shown either 
that high anti-FHA levels inhibit opsonophagocytosis24 or that anti-Prn is important for opsonophagocytosis25. 
These differences may be explained by the various read-outs (bacterial uptake by flow cytometry, respiratory burst 
or microscopy) used to determine opsonophagocytosis, as well as the timing of serum or plasma sample collection. 
Effective-IgG levels to FHA, a vaccine antigen and major adhesion of B. pertussis26, best predicted the variances 
of the opsonophagocytosis indices. FHA-antibodies are expected to bind to the bacterial membrane and mediate 
bacterial uptake by engaging Fc-γ receptors on neutrophils27. It remains unknown whether FHA-specific anti-
bodies generated upon infection and vaccination are similar in functionality. Antibodies against the additionally 
included outer membrane-localised antigens LOS28, Vag8 and BrkA29,30, important immune modulators medi-
ating resistance against antimicrobial peptides (LOS) and complement (LOS, Vag8 and BrkA), were not predic-
tive for the opsonophagocytosis indices according to the RF analysis. It is possible that these antibodies are of 
an IgG subclass that does not mediate opsonophagocytosis or that the antigen is masked on the bacterial mem-
brane. However, this does not exclude other functional roles for human antibodies against these additional sur-
face antigens. Monoclonal antibodies directed against LOS were found to be important in preventing B. pertussis 
infection in a mouse model31 and BrkA-specific antibodies have been implicated in bactericidal killing of B. per-
tussis32. Further studies should address these matters. The second best predictor for opsonophagocytosis was the 
presence of antibodies directed to Ptx. Because this toxin is generally secreted by B. pertussis and induces high levels 
of antibodies following infection16,33,34, we speculate that the association found in the RF model is not mechanis-
tically related. Interestingly, FHA- and Ptx-specific antibodies did not show an increased avidity in the recovered 
pertussis patients suggesting that perhaps high antibody avidity for these antigens is not necessarily important for 
opsonophagocytosis of B. pertussis. Whether the FHA, and possibly Ptx, antibodies are mechanistically related to 
neutrophil opsonophagocytosis will have to be verified by either depleting or and/or isolating these antibodies from 
plasma, as well as by performing the OPA with B. pertussis that do not express FHA or Ptx. To determine whether 
these antibodies indeed also protect from colonisation with B. pertussis, an in vitro model using differentiated 
human airway epithelial cells35,36 may be used for validation. Moreover, eventually the novel controlled human 
infection pertussis model37 could be valuable to determine protection from colonization by specific antibodies.
Although FHA- and Ptx- specific antibodies were the best predictors for opsonophagocytosis in our model, 
their presence only explained 28% of the opsonophagocytosis indices variances. Adenylate cyclase toxin 
(ACT) produced by B. pertussis reduces phagocytosis and subsequent bacterial killing by neutrophils14,38. 
Previously, antibodies directed against this toxin have been shown to promote phagocytosis of B. pertussis via 
toxin-neutralization39. ACT is not only secreted but also remains associated to the bacterial membrane by inter-
acting with FHA40,41. ACT-specific antibodies could hence also opsonize B. pertussis. Although ACT was not 
included in the antigen panel of this study, it is likely that part of the unexplained variances can be attributed to 
ACT-specific antibodies. Also, other specificities cannot be excluded, as the naturally acquired or vaccine-induced 
B. pertussis serum reactomes are very diverse and broad42. Future studies should explore whether ACT-specific or 
other B. pertussis-specific antibodies further predict opsonophagocytosis.
This work represents a first step towards identifying CoPs by the combined analysis of different parameters of 
B. pertussis-specific antibodies from (ex) pertussis patients. These findings should be interpreted with caution as 
the longitudinal pertussis cohort used is small and includes individuals of different ages with different vaccination 
status and most likely previous infection backgrounds. Due to the low sample size we were unable to analyse our 
data by grouping the individuals according to age. Furthermore, our cohort does not include young infants whom 
are the main victims of severe pertussis. The induction of B. pertussis-specific antibodies and their functional 
properties may differ between infants and the older individuals in our cohort, possibly due to the presence of 
maternal antibodies43, which should be taken into account when developing novel childhood pertussis vaccines.
We furthermore suggest exploring antibody characteristics such as subclass and fucosylation status44 which 
can influence opsonizing capacity or other antibody effector functions. Additionally, protective mechanisms 
including neutrophil respiratory burst45 and subsequent killing, as well as complement-mediated killing of B. 
pertussis46–48 could be studied. Recently, levels of specific memory B cells, that can give rise to a fast increase in 
antibody levels upon an infection with B. pertussis, were implied in protection20,49,50. Moreover, it is clear that not 
only antibodies or B cells are involved in protection against pertussis, as T helper 1(Th1) and Th17 cells49,51 have 
also been implicated as very important players in the protective immune response against B. pertussis. Taken 
together, the pertussis field should broaden the way identification of CoPs is approached and be open to multifac-
torial CoPs against pertussis, which could be a combination of antibody levels, antibody functionality as well as 
B. pertussis specific T and B cell responses. With respect to antibodies, integration of different specific antibody 
parameters may bring the field closer to the identification of the required CoPs against pertussis.
Materials and Methods
Ethics. Participants donating blood for plasma isolation were Dutch symptomatic (ex-) pertussis patients 
selected from a cross-sectional observational study previously described (Specifieke Kinkhoest Immuniteit; 
SKI)13. The study was approved by the accredited Medical Research Ethics Committee (MREC) STEG followed 
by management of the METC UMC Utrecht (Dutch Central Committee on Research Involving Human Subjects 
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(CCMO) nr: NL16334.040.07). Collection of all samples used was conducted according to the principles of the 
Declaration of Helsinki and all participants, parents/guardians of minor participants and blood donors for pri-
mary cell isolation provided written informed consent. Samples were treated anonymously.
Study population. Forty individuals (age 7–73 years, median 49.4 years, at inclusion; male/female ratio: 
0.35/0.65) who presented clinical pertussis symptoms and were physician-diagnosed with pertussis, either by 
PCR or serology, were selected from the SKI cohort, a Dutch natural infection cohort established between 2008 
and 201213. Selection was based on whether two longitudinal samples were available namely, early after diagnosis 
(1.7 to 9.0 weeks, median 3.15 weeks, i.e. symptomatic) when the patients still presented pertussis symptoms 
and years later (2.7 to 4.7 years, median 3.2 years, i.e. recovered) when the patients had recovered from clinical 
disease. An additional 20 household contacts from the SKI cohort (age 7.9–48.2 years, median 21.4 years; male/
female ratio 0.5/0.5, i.e. controls) who were seronegative (negative anti-Ptx titres) for pertussis and vaccinated 
according to the Dutch national immunisation program were also selected (Fig. 1).
Plasma collection and neutrophil isolation. Blood samples in the SKI study were collected using 
vacutainer CPT cell preparation tubes (BD Biosciences, San Jose, CA, USA). Plasma was isolated using stand-
ard procedures and stored at −80 °C. Plasma was heat inactivated (HI) for 20 minutes at 56 °C. Human neutro-
phils were isolated from donor blood as described previously52. Briefly, heparinized venous blood obtained from 
healthy donors in vacutainer collection tubes (BD Biosciences) was twice diluted in PBS (Gibco) and layered onto 
a gradient of Ficoll-Paque Premium (GE Healthcare Life Sciences) and Histopaque-1119 (Sigma-Aldrich). After 
centrifugation for 20 minutes at 400 g, neutrophils were collected from the Histopaque layer and washed with 
RPMI-1640 (Gibco), supplemented with 0.05% human serum albumin (HSA, Sanquin). Neutrophils were used 
in the opsonophagocytosis assay shortly after isolation.
Bacteria. B. pertussis B191717 was transformed with plasmid pCW505 resulting in cytoplasmic expression 
of GFP (B1917-GFP)25. Bacteria were grown on Bordet-Gengou agar plates containing 15% sheep blood (BD 
Biosciences) supplemented with 30 µg/ml gentamycin (Merck, Darmstadt, Germany) at 35 °C, 5% CO2 for four 
days. Subsequently, bacteria were recultured in Thalen-IJssel medium53 overnight (start OD 0.05, 35 °C, 130 rpm) 
until mid-log phase (OD 0.7) was reached before use.
Pertussis antigens. Ptx and FHA were obtained from Kaketsuken (Obuko, Japan). Fim2 was a kind gift 
from Dr. A Gorringe, Fim3 and Prn were purified in-house. LOS was extracted from strain B1917 by means of 
hot phenol-water as previously described54. OMVs of B1917, containing various outer membrane antigens, were 
generated as previously described55 with some modifications and recombinant passenger domains of Vag8 and 
BrkA were expressed in Escherichia. coli as described elsewhere47.
Multiplex immunoassay. Levels of total IgG directed against B. pertussis antigens Ptx, FHA, Prn, Fim2, 
Fim3, Vag8, BrkA, LOS and OMV were measured in HI-plasma samples by an in-house multiplex immunoassay 
(MIA) described earlier13. The International WHO pertussis standard (NIBSC 06/140) served as reference for 
IgG levels against Ptx, FHA and Prn (International units, IU/ml). Human Normal Immunoglobulin solution 
for infusion (KIOVIG, Baxalta, Belgium) was used as an in-house reference to measure levels of IgG against the 
remaining six antigens, expressed as arbitrary units per ml (AU/ml) based on observed relative magnitudes of 
fluorescence intensity where KIOVIG was set at 500 AU/ml. For detection, goat-anti-human IgG-PE (Jackson 
ImmunoResearch, USA) was used. Analysis was performed with a Bio-Plex 200 using Bio-Plex Manager software 
version 5.5 (Bio-Rad Laboratories, West Grove, PA, USA). The various antigen coupled bead regions were not 
found to interfere with one another.
Avidity assay. The avidity of pertussis-specific IgG antibodies was measured in the MIA using HI-plasma as 
described previously56 with modifications. Briefly, plasma samples were allowed to bind for 45 minutes with the 
respective pertussis antigen coupled to fluorescently labelled microspheres. After washing, samples were incu-
bated for 15 minutes in PBS either in the absence or presence of 9 M urea, to elute lower-avidity antibodies. 
Subsequently, samples were washed, goat-anti-human IgG-PE (Jackson ImmunoResearch, USA) was used as 
detection antibody and analysis was performed with a Bio-Plex 200 using Bio-Plex Manager software version 5.5 
(Bio-Rad) The avidity index (AI) was expressed as a percentage of the remaining IgG levels in the presence of urea 
relative to the IgG levels measured in PBS only.
Opsonophagocytosis assay. Opsonophagocytosis of B. pertussis B1917 by human neutrophils was eval-
uated using a method described in literature with minor modifications27,57. Briefly, B1917-GFP (multiplicity of 
infection is 70) were opsonized with 5% HI-plasma in RPMI supplemented with 0.3% human serum albumin 
(HSA, Sanquin) for 20 minutes at 37 °C. Subsequently, freshly isolated neutrophils (7.5 × 104 cells) were added 
in a total volume of 50 µl and incubated for 25 minutes at 4 °C. After a wash step with cold RPMI-HSA, neutro-
phils were resuspended in RPMI-HSA and incubated for 30 minutes at 37 °C. The incubation times used were 
selected based on OPA pilot experiments. Cells were fixed with 1.5% paraformaldehyde and visualized using the 
FACSCanto II (BD Bioscience). The assay was performed in duplicate on three different days. To correct for plate 
and day differences, a standalone-control plasma sample was taken along on each plate for each day and a plate 
factor was calculated. The arbitrary opsonophagocytosis indices were calculated by dividing the mean fluorescent 
intensity (MFI) obtained in the presence of plasma by the MFI obtained upon incubating cells with bacteria with-
out plasma, corrected for the plate factor.
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Data analysis. Differences in antibody levels and opsonophagocytosis indices between the groups were 
tested with one-way analysis of variance (ANOVA) followed by post-hoc tests (Welch Two Sample t-test or paired 
t-test). For differences in the AI a paired t-test was performed. P values ≤ 0.05 were considered statistically signif-
icant. The false discovery rate was controlled at the level of 10% by applying the Benjamini-Hochberg method to 
the results of all tests (Supplementary Table 2).
Principal component analysis (PCA) was used to explore dis(similarities) among the antibody levels, AI and 
opsonophagocytosis indices of the three groups.
To determine which of the measured antibodies were most predictive for the observed opsonophagocytosis, 
a random forest (RF) analysis was performed58. The model considered in this analysis uses for each antigen the 
effective-IgG level, which we define as the logarithm of the product of IgG levels and AI (IgG*AI). A multiple 
linear regression analysis using the same effective-IgG levels was also performed. Descriptive statistics of the data 
can be found in Supplementary Table 1.
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